SOLENO THERAPEUT. DL-001 (6XC F) stock market data APIs
€39.9901
0.11(0.3%)
as of December 19, 2025
Try our APIs with
free plan!
SOLENO THERAPEUT. DL-001 Financial Data Overview
Price chart is built with
Anychart
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Prev. Close
39.9901
Open
40.0991
High
40.0991
Low
39.8532
52 wk Range
36.56-76.65
Market Cap
2 133 M
Shares Outstanding
53 710 K
Revenue
98 675 K
EPS
-0.9
Beta
-3.152
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SOLENO THERAPEUT. DL-001 data using free add-ons & libraries
Get SOLENO THERAPEUT. DL-001 Fundamental Data
SOLENO THERAPEUT. DL-001 Fundamental data includes:
- Net Revenue: 98 675 K
- EBITDA: -82 259 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2022-06-30
- EPS/Forecast: -0.9
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SOLENO THERAPEUT. DL-001 News
New
Soleno Therapeutics (SLNO) Valuation Check After Wolfe Research’s Optimistic New Coverage and Stock Pop
Soleno Therapeutics (SLNO) is back on traders’ screens after Wolfe Research kicked off coverage with an upbeat view, helping push the stock up about 5% as investors reassess the risk reward setup. ...
How Soleno Therapeutics' Audit Committee Leadership Transition At Soleno Therapeutics (SLNO) Has Changed Its Investment Story
Earlier this month, Soleno Therapeutics announced the passing of long-time board member and Audit Committee Chair William G. Harris, while indicating that experienced director Andrew Sinclair, recogni...
Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win
Rhythm Pharmaceuticals said Thursday said it would send it would send its leading drug into registrational testing for Prader-Willi. Continue Reading
Is Soleno Therapeutics, Inc. (SLNO) The Cheap Healthcare Stock To Buy Heading Into 2026?
Soleno Therapeutics, Inc. (NASDAQ:SLNO) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Soleno Therapeutics, Inc. (NASDAQ:SLNO) has a consensus Buy rating, as all 13 a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
